未登录

J

Joel M. Trugman

AbbVie

H指数:37

被引数:5,079

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study

IF4

2026-08-200

OAAI

Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans

人用阿托格普兰的脑脊液和血浆浓度

Clinical and Translational Science

IF2.8

2026-05-270

OAAI

Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open-Label Trial

ubrogepant在具有偏头痛病史的参与者中的血浆和脑脊液暴露：一项1b期开放标签试验的结果

CTS-Clinical and Translational Science

IF2.8

2026-04-210

OAAI

Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine

阿托 gepant 用于偏头痛预防性治疗的长期能效、有效性和功能性结局

IF4.6

2025-08-190

OA

Milk and plasma pharmacokinetics of single-dose ubrogepant in healthy lactating women

单剂量ubrogepant在健康哺乳期妇女中的乳汁和血浆药代动力学

IF4

2025-05-200

OA

Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials

ubrogepant和atogepant对男性和女性偏头痛的疗效: 随机临床试验的二次分析

IF4.6

2025-02-210

PRE

Characterizing Prodrome (Premonitory Phase) in Migraine

偏头痛的前驱症状 (先兆期)

NEUROLOGY-CLINICAL PRACTICE

IF3.2

2025-02-012

PRE

Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials

IF4.6

2024-12-080

PRE

Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis

偏头痛预防性治疗期间使用atogepant减轻体重: 汇总分析

IF4.6

2024-12-080

OA

Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study

IF4

2024-11-211

OAAI

Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome

IF8.5

2024-09-240

OAAI

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial

在随机，双盲，3期PROGRESS试验中，Atogepant对有或没有急性药物过度使用的慢性偏头痛的疗效

IF8.5

2024-07-233

OAAI

Atogepant: Mechanism of action, clinical and translational science

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-01-106

OA

Ubrogepant: Mechanism of action, clinical and translational science

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-01-102

OA

Efficacy of ubrogepant for the treatment of migraine symptoms during the prodrome (premonitory phase): Results from the prodrome trial

JOURNAL OF THE NEUROLOGICAL SCIENCES

IF3.2

2023-12-010

PRE

Ubrogepant for the acute treatment of migraine when administred during the prodrome: Results from a phase 3, randomized, double-blind, placebo-controlled, crossover study

JOURNAL OF THE NEUROLOGICAL SCIENCES

IF3.2

2023-12-010

PRE

Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA

IF88.5

2023-12-0123

PRE

Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials

IF4

2023-10-240

OAAI

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo- controlled, phase 3 trial

IF88.5

2023-09-0146

PRE

Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis

乌布罗格普特急性治疗月经前偏头痛发作的安全性和有效性: 事后分析

IF4

2023-09-014

OAAI